Omega Funds

Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.

Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.

Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.

Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

Paratek Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapies for life-threatening infectious diseases and other serious health conditions. The company’s lead products include NUZYRA, an oral and intravenous broad-spectrum antibiotic effective against community-acquired bacterial pneumonia and acute bacterial skin infections, and SEYSARA, a tetracycline antibiotic for treating moderate to severe acne vulgaris. Paratek’s research is anchored in tetracycline chemistry and biology, and the company actively collaborates with partners such as Zai Lab and Allergan, as well as academic institutions like Tufts University. Additionally, Paratek engages in cooperative research with the U.S. Army Medical Research Institute of Infectious Diseases to explore treatment options against infectious agents. Founded in 1996, Paratek continues to expand its focus on addressing severe diseases, including research into multiple sclerosis and systemic inflammatory conditions.